GLP-1 Agonists, Honestly

July 3, 2026 13 min read The Human Machine

glp-1semaglutidetirzepatideincretin-hormonesobesity-medicineendocrinology

Contents

A hormone your gut has been secreting after every meal for your entire life, with a native half-life measured in single-digit minutes, is now the active ingredient in some of the best-selling drugs in pharmaceutical history — not because anyone invented a new biological mechanism, but because someone figured out how to keep that hormone’s signal turned on for a full week instead of two minutes. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are GLP-1 receptor agonists, and the honest version of their story is neither the miracle-cure framing nor the fad-drug dismissal — it’s a real, mechanistically well-understood intervention in the incretin system, with real effect sizes, real side effects, a real muscle-loss trade-off, and a real answer to what happens when you stop, all of which are more interesting and more useful to know than either extreme.

The Incretin System: Why a Gut Hormone Controls Blood Sugar and Appetite

The starting observation, made decades before anyone knew what GLP-1 was, is called the incretin effect: glucose taken orally provokes a substantially larger insulin response from the pancreas than the exact same amount of glucose delivered directly into the bloodstream by IV. Something released by the gut in response to food was amplifying the pancreas’s insulin output — and that something turned out to be a pair of hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), released by specialized L cells and K cells lining the intestine as food passes through.

GLP-1 does three things simultaneously once it’s released and binds its receptor: it stimulates the pancreas to release insulin in a glucose-dependent manner (more glucose present, more insulin released — it doesn’t force insulin release when blood sugar is already low, which is part of why it carries less hypoglycemia risk than older insulin-secretagogue drugs), it suppresses glucagon release from the pancreas’s alpha cells, and it acts on receptors in the stomach and hypothalamus to slow gastric emptying and increase satiety signaling. The GLP-1 receptor itself is a class B G-protein-coupled receptor, and its downstream cAMP-based signaling cascade is the same general GPCR logic covered in /posts/peptide-hormones-vs-steroid-hormones/ — a peptide hormone binding a surface receptor and triggering a fast, amplifying second-messenger cascade rather than the slower gene-transcription route steroid hormones use.

FOOD ENTERS GUT
      |
      v
L cells (small intestine) release GLP-1
K cells (proximal gut) release GIP
      |
      +----------------> PANCREAS: insulin release (glucose-dependent)
      |                             glucagon suppression
      |
      +----------------> STOMACH: slows gastric emptying
      |
      +----------------> HYPOTHALAMUS: increases satiety signaling
      |
      v
NATIVE GLP-1 half-life: ~2 minutes
      |
      v
Degraded by DPP-4 enzyme almost immediately

That last line is the entire drug-development problem in one sentence. Native GLP-1 is degraded by the enzyme dipeptidyl peptidase-4 (DPP-4) within about two minutes of release, which makes the natural hormone itself essentially useless as an injectable drug — by the time it reached a therapeutic target, it would already be gone.

From Gila Monster Venom to a Blockbuster Drug Class

The fix for GLP-1’s two-minute half-life came from an unlikely source. In 1992, VA researcher John Eng isolated a peptide from Gila monster venom he named exendin-4, and found it lowered blood glucose in diabetic mice for hours rather than minutes. Exendin-4 shares roughly 53% sequence identity with human GLP-1 and activates the same receptor — but its structure resists DPP-4 degradation, because the Gila monster’s own metabolism, adapted to eating only a handful of times per year, depends on a version of this hormone that stays active long enough to manage a massive, infrequent nutrient load. Eng spent three years trying to interest a pharmaceutical company in the discovery before it was eventually developed into exenatide (Byetta), approved by the FDA in 2005 as the first GLP-1 receptor agonist drug — twice-daily injections, a direct descendant of lizard venom, and proof the receptor-agonism approach worked in humans.

Semaglutide and tirzepatide extend the same idea further using a different chemical trick: rather than relying on a naturally DPP-4-resistant sequence, they attach a fatty-acid side chain to the peptide backbone that lets the molecule reversibly bind circulating albumin. Albumin-bound peptide is protected from both renal clearance and enzymatic degradation, which stretches the effective half-life from exenatide’s several hours to roughly a week — the difference between twice-daily injections and a once-weekly pen, which is as much a delivery-engineering achievement as it is a pharmacology one.

Semaglutide vs. Tirzepatide: One Receptor vs. Two

The two drugs currently driving most of the clinical and commercial attention differ in one structural decision: semaglutide agonizes the GLP-1 receptor alone, while tirzepatide is a dual agonist, activating both the GLP-1 receptor and the GIP receptor. That second receptor turns out to matter more than GIP’s historically secondary reputation would suggest — head-to-head trials have shown tirzepatide producing meaningfully larger weight-loss effect sizes than semaglutide, along with somewhat fewer GI side effects at comparable efficacy in some preclinical comparisons.

Drug	Receptor target	Brand names	Typical pivotal-trial weight loss
Semaglutide	GLP-1 only	Ozempic (diabetes), Wegovy (obesity)	~15% average body weight
Tirzepatide	Dual GLP-1 + GIP	Mounjaro (diabetes), Zepbound (obesity)	~21% average body weight
Exenatide (for reference, 2005)	GLP-1 only, short-acting	Byetta	Modest, glucose-control-focused; not developed as a weight-loss drug

The dosing itself follows a slow titration schedule in both drugs, not because of some regulatory formality but because the same GI mechanisms that produce the therapeutic effect — slowed gastric emptying, reduced appetite — cause dose-dependent nausea if ramped too quickly. A representative semaglutide titration schedule looks like this:

# semaglutide subcutaneous titration schedule (representative, weekly dosing)
week  1- 4: 0.25 mg   # initiation dose, not intended to be clinically effective
week  5- 8: 0.5  mg
week  9-12: 1.0  mg
week 13-16: 1.7  mg
week 17+  : 2.4  mg   # target maintenance dose for obesity indication

Every step-up is a deliberate trade-off between reaching an effective dose and tolerating the GI side effects along the way, and clinicians commonly extend individual steps for patients who don’t tolerate a given increase well.

The Real Effect Sizes and Side Effects

The double-digit percentage weight-loss figures are genuine, replicated across multiple large randomized trials, and represent a substantially larger effect size than essentially any prior pharmacological approach to obesity — but “real and large” is not the same as “free of downsides,” and the honest picture requires both halves.

Category	What the trials show
Weight loss magnitude	~15% (semaglutide) to ~21% (tirzepatide) average body weight reduction in pivotal obesity trials
Most common side effects	Nausea, vomiting, diarrhea, constipation — largely dose-dependent and concentrated during titration
Less common but serious	Gallbladder disease/gallstones, pancreatitis (rare but documented), and case reports of severe gastroparesis
Glycemic benefit (diabetes indication)	Meaningful reduction in HbA1c independent of the weight-loss effect, via the glucose-dependent insulin/glucagon mechanism
Cardiovascular signal	Some trials have shown reduced major adverse cardiovascular event rates in high-risk populations, a genuinely significant finding beyond weight loss alone

The GI side effects are mechanistically the same slowed-gastric-emptying and satiety signaling that produce the drug’s benefit — it’s not a separate toxicity bolted onto an otherwise clean mechanism, it’s the same lever running strong enough to be felt as discomfort in a meaningful fraction of patients, which is exactly why the titration schedule exists.

The Muscle-Loss Concern

This is the part of the honest accounting that gets the least attention in marketing material and the most attention in clinical follow-up literature. Weight loss from any method — caloric restriction, bariatric surgery, GLP-1 agonism — comes from a mix of fat and lean tissue, and the lean-tissue fraction with GLP-1 drugs has turned out to be higher than many clinicians initially expected. In the STEP 1 trial, roughly 40% or more of the total weight lost on semaglutide was lean mass rather than fat mass in several analyses — figures in that range, sometimes reported closer to 40-45%, are noticeably higher than the roughly 20-30% lean-mass fraction typically seen with diet-only weight loss in the general obesity literature.

This matters clinically because muscle mass isn’t just a cosmetic or strength concern — it’s tied to insulin sensitivity, resting metabolic rate, mobility, and, in older adults, mortality risk, which means losing a disproportionate share of lean tissue partially undercuts some of the metabolic benefit the drug is otherwise providing. The mitigation isn’t exotic: studies incorporating structured resistance training and adequate dietary protein intake alongside GLP-1 therapy show the lean-mass loss can be reduced close to what would be expected from fat-focused weight loss alone. The concern is not that the drugs cause a unique, mysterious form of muscle wasting — it’s that a purely pharmacological intervention that dramatically reduces caloric intake, without a deliberate resistance-training and protein-intake program layered on top, defaults to losing tissue indiscriminately rather than preferentially preserving muscle, and that’s a program design gap rather than a drug design flaw.

What Happens When You Stop

The most consequential honest answer in this entire drug class is what happens after discontinuation, and it’s been directly studied. In the STEP 1 trial extension, participants who stopped semaglutide after a year of treatment (while also stopping the accompanying lifestyle intervention) regained, on average, about two-thirds of the weight they had lost — going from a substantial reduction at treatment end to a much smaller net loss from baseline one year after stopping. The appetite-suppression and satiety effects the drug provides are the direct pharmacological cause of the maintained weight loss; once the receptor is no longer being agonized, the physiological drive toward the pre-treatment weight set point reasserts itself for most patients, the same basic phenomenon behind weight regain after most non-surgical obesity interventions, just documented here with unusually precise trial data.

Timepoint	Semaglutide group (STEP 1 extension)
End of 68-week treatment period	~17% average weight loss from baseline
One year after stopping the drug	Roughly two-thirds of the treatment-period loss regained
Net result at one year post-discontinuation	Still a meaningful net loss from original baseline, but far smaller than the on-drug figure

The practical implication that follows directly from this data — not an opinion layered on top of it, but the trial’s own finding — is that these drugs currently behave less like a course of antibiotics that cures a condition and more like a blood pressure medication that manages one for as long as it’s taken. That reframing matters enormously for how patients, insurers, and clinicians should think about the multi-year cost and commitment involved, independent of how well the drug works while it’s being used.

The Access Problem Nobody’s Prescription Pad Solves

None of the physiology above matters much to a patient who can’t sustain the treatment, and the cost structure of this drug class is its own honest complication layered on top of the medical one. List price for Wegovy runs roughly $1,350 to $1,640 per month without insurance; Zepbound averages around $1,270 per month. Manufacturer savings programs and discount cards can bring cash-pay costs down substantially — into the low hundreds per month for some dose tiers — but that’s still $2,000 to $12,000 a year out of pocket depending on dose, program, and whether a patient qualifies for the steepest discount tiers.

Insurance coverage is inconsistent and typically gated: most commercial insurers require prior authorization tied to a documented BMI threshold (commonly 35 or higher, or lower with a qualifying comorbidity) and evidence of a prior lifestyle-intervention attempt, and even approved coverage often carries a copay in the tens to low hundreds of dollars per month. Medicare historically excluded obesity-only GLP-1 coverage by statute, treating weight loss as a lifestyle rather than a medical indication — a policy gap partially addressed by a temporary Medicare bridge program offering eligible beneficiaries broader access at a flat $50 monthly copay starting mid-2026, though as a time-limited program rather than a permanent fix.

The mechanistic story earlier in this post — the two-thirds regain finding from the STEP 1 extension — makes this cost structure more than an access footnote: if the benefit genuinely requires continued treatment to persist, then the price a given patient’s insurance (or lack of it) settles on isn’t just a barrier to starting therapy, it’s a determinant of whether the physiological benefit is available at all over the years-long horizon these drugs actually require to matter.

Honest Trade-offs

The effect sizes are genuinely large by the standards of obesity pharmacology, but they are not surgical-scale. Bariatric surgery still generally produces larger and more durable percentage weight loss than any current GLP-1 drug; these drugs are a major advance in the pharmacological tier, not a replacement for surgery in every case where surgery would otherwise be indicated.
GI side effects are the mechanism working, not a separate malfunction. Slower gastric emptying is simultaneously the appetite-suppression mechanism and the nausea mechanism, which is why titration speed — not just final dose — is a real clinical lever for tolerability.
The lean-mass loss is a real, measurable trade-off, not an unfounded internet concern. It’s mitigable with resistance training and adequate protein, but that mitigation requires a deliberate program most patients aren’t automatically given alongside a prescription.
Weight loss is not durable without continued treatment for most patients based on current trial data. The two-thirds regain figure from the STEP 1 extension is a genuine finding that should shape expectations and cost-benefit conversations, not a talking point to be minimized in either direction.
The dual-receptor mechanism in tirzepatide shows the class is still evolving, not fully optimized. Larger effect sizes from adding GIP agonism suggest current single-mechanism drugs may not represent the ceiling for this approach, and ongoing trials of triple agonists targeting GLP-1, GIP, and glucagon receptors together are a direct extension of that same logic.

Verdict

GLP-1 agonists are a legitimate pharmacological achievement built on decades-old, well-understood incretin physiology, not a shortcut or a gimmick — the mechanism by which they work is the same mechanism your gut has been using after every meal for your entire life, engineered to stay active for a week instead of two minutes. The honest accounting shows real, large effect sizes on weight and glycemic control; real, mechanistically-linked GI side effects; a real and underappreciated muscle-loss trade-off that resistance training and protein intake can substantially offset; and a real answer, backed by trial data rather than speculation, that the benefit is contingent on continued use rather than a one-time metabolic reset. None of that makes the drugs less valuable — it makes them a chronic-disease-management tool with a strong evidence base, which is a more useful thing to understand than either “miracle cure” or “dangerous fad” framing, and it’s the framing that should actually drive how patients and clinicians plan for using them.